Register
Exparel gets FDA go-ahead for pain relief post-shoulder surgery |
Journal Updates
eMediNexus Coverage from: 
Exparel gets FDA go-ahead for pain relief post-shoulder surgery
eMediNexus,  12 April 2018
remove_red_eye 690 Views
#Anesthesiology #General Surgery #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for bupivacaine liposomal injectable suspension (Exparel, Pacira Pharmaceuticals Inc) for use as an interscalene brachial plexus nerve block to provide regional analgesia following shoulder surgery in adults.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!